Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes

Michael Maeng, Philippe Gabriel Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Takeshi Kimura, Gregory Y.H. Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
2019 JACC: Cardiovascular Interventions  
The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.
doi:10.1016/j.jcin.2019.07.059 pmid:31806216 fatcat:4xcjfqee6ra7bpiuvbmj2cclhu